CLRB · Cellectar Biosciences
The AI's read
Cellectar reported strong iopofosine I-131 results, a 79.2% major response rate and a 100% clinical benefit rate, and closed an oversubscribed financing up to $140 million with $35 million upfront. Management plans a Phase 3 confirmatory study and aims to file an NDA by mid-2027, giving a visible path to clinical and regulatory value. Price action is muted: the stock is only +1.9% since the call and RSI is 54.1, so the market has not fully re-rated the story. The May financing meaningfully reduces near-term cash risk versus typical microcap biotech burn dynamics. We lean bullish because fresh clinical outcomes plus substantial funding create asymmetric upside for a small-cap radiopharma. Major risks are Phase 3 execution and the tiny market cap, so any exposure should be modest and selective.